FDA approves first treatment against MERS-CoV coronavirus


The US Food and Drug Administration (FDA) announced on Friday that it has authorized Panavira® Endotoxin Injection, R+L® Injection, and Coronavirus Booster Shots, for adults ages 18 to 64 who develop flulike symptoms within four days of the onset of an acute respiratory tract infection caused by the coronavirus.

Also known as the MERS-CoV coronavirus, this new medication is for adults who are negative for the disease’s positive genetic marker and likely cannot be vaccinated with the standard “first line” precautionary trivalent shot. Other key uses of the new therapy are positive genetic tests for adults with active sign of infection.

One hundred million doses of the vaccine will be available beginning in January 2019, according to the FDA.

According to the Centers for Disease Control and Prevention (CDC), the MERS-CoV coronavirus is one of the most deadly diseases to ever arise from animal to human interactions. In 2010, the coronavirus was responsible for the first human case of transmission between people in Dubai. Since that time, MERS-CoV has spread across the globe and caused more than 400 illnesses, 132 deaths and remains one of the most extensive community-acquired respiratory viruses worldwide. According to the World Health Organization (WHO), the first cases in humans were reported in a confirmed case in Saudi Arabia in 2012. Since then, the most recent report of confirmed cases was received in April 2018, and unfortunately, there have been six new reported cases since.

Significant medical conditions, such as large blood vessels, vascular diseases, liver disease, atherosclerosis, cardiac conditions and other disorders, should be addressed before receiving the therapy, according to the FDA.

To view the complete data safety and effectiveness statement in support of the approval of the drug, visit the FDA’s website.

Leave a Comment